Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S K Austin

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
British Journal of Haematology|November 13, 2008
The JAK2 V617F mutation and thrombosisS K Austin, J R Lambert
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 1, 2014
ITI choice for the optimal management of inhibitor patients - from a clinical and pharmacoeconomic perspectiveJ Oldenburg, S K Austin, C M Kessler
British Journal of Haematology|May 31, 2008
Audit of the peri-delivery use of unfractionated heparin in women on therapeutic low-molecular weight heparinJ R Lambert, S K Austin, D Peebles, et al.
Lupus|December 22, 2012
Mycophenolate mofetil-induced erythroid hypoplasia in a patient with systemic lupus erythematosusT Doherty, S K Austin, B Newell, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 21, 2016
Efficacy, safety and pharmacokinetics of a new high-purity factor X concentrate in subjects with hereditary factor X deficiencyS K Austin, K Kavakli, M Norton, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 17, 2016
Pharmacokinetics of a high-purity plasma-derived factor X concentrate in subjects with moderate or severe hereditary factor X deficiencyS K Austin, C Brindley, K Kavakli, et al.
Internal Medicine Journal|September 27, 2003
Recovery of pure red-cell aplasia secondary to antierythropoietin antibodies after cessation of recombinant human erythropoietinU Panchapakesan, S K Austin, A Shafransky, et al.
Journal of Thrombosis and Haemostasis : JTH|September 9, 2006
Pregnancy loss, tissue factor pathway inhibitor deficiency and resistance to activated protein CC Gardiner, H Cohen, S K Austin, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 10, 2015
Ongoing risk of thrombosis with factor XI concentrate: 5 years experience in two centresP Batty, A Honke, L Bowles, et al.
British Journal of Haematology|March 18, 2008
The VWF/ADAMTS13 axis in the antiphospholipid syndrome: ADAMTS13 antibodies and ADAMTS13 dysfunctionS K Austin, R D Starke, A S Lawrie, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
British Journal of Haematology|November 13, 2008
The JAK2 V617F mutation and thrombosisS K Austin, J R Lambert
Haemophilia : the Official Journal of the World Federation of Hemophilia|July 1, 2014
ITI choice for the optimal management of inhibitor patients - from a clinical and pharmacoeconomic perspectiveJ Oldenburg, S K Austin, C M Kessler
British Journal of Haematology|May 31, 2008
Audit of the peri-delivery use of unfractionated heparin in women on therapeutic low-molecular weight heparinJ R Lambert, S K Austin, D Peebles, et al.
Lupus|December 22, 2012
Mycophenolate mofetil-induced erythroid hypoplasia in a patient with systemic lupus erythematosusT Doherty, S K Austin, B Newell, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|May 21, 2016
Efficacy, safety and pharmacokinetics of a new high-purity factor X concentrate in subjects with hereditary factor X deficiencyS K Austin, K Kavakli, M Norton, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|February 17, 2016
Pharmacokinetics of a high-purity plasma-derived factor X concentrate in subjects with moderate or severe hereditary factor X deficiencyS K Austin, C Brindley, K Kavakli, et al.
Internal Medicine Journal|September 27, 2003
Recovery of pure red-cell aplasia secondary to antierythropoietin antibodies after cessation of recombinant human erythropoietinU Panchapakesan, S K Austin, A Shafransky, et al.
Journal of Thrombosis and Haemostasis : JTH|September 9, 2006
Pregnancy loss, tissue factor pathway inhibitor deficiency and resistance to activated protein CC Gardiner, H Cohen, S K Austin, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 10, 2015
Ongoing risk of thrombosis with factor XI concentrate: 5 years experience in two centresP Batty, A Honke, L Bowles, et al.
British Journal of Haematology|March 18, 2008
The VWF/ADAMTS13 axis in the antiphospholipid syndrome: ADAMTS13 antibodies and ADAMTS13 dysfunctionS K Austin, R D Starke, A S Lawrie, et al.
Pageof 2